Milestone Pharmaceuticals' Q2 2026 revenue hits $0.6M with over 800 prescribers for Cardamist, as commercial coverage exceeds 50% of lives.
Milestone Pharmaceuticals Inc. reported Q2 2026 product revenue of $0.6 million, marking its first full financial quarter since the commercial launch of Cardamist in February. The revenue reflects a growing acceptance of the drug in the market, with a significant increase in both prescriber and patient engagement, signaling a positive trajectory for future sales.
Key Takeaways
- First full quarter revenue reached $0.6 million, indicating early commercial traction for Cardamist.
- Unique prescribers increased dramatically to over 800 in Q2, up from approximately 200 in Q1, showcasing strong physician interest and engagement.
- Commercial coverage for Cardamist now exceeds 50% of commercially insured lives, up from 25% at the end of Q2, expected to enhance patient access and prescription growth.
- Total prescriptions for Cardamist rose to over 1,200 in Q2, compared to around 300 in Q1, reflecting a positive adoption rate among patients.
- Net loss for Q2 was $28.6 million, or $0.21 per share, compared to a net loss of $13 million, or $0.20 per share, in Q2 2025.
Growing Market Acceptance Signals Positive Outlook
Milestone's financial results for Q2 2026 demonstrate strong early adoption of Cardamist, a self-administered treatment for paroxysmal supraventricular tachycardia (PSVT). Total revenue of $0.6 million was achieved during the first full quarter post-launch, indicating initial market traction. The company reported more than 800 unique prescribers in Q2, a notable increase from approximately 200 in Q1. This growth in prescriber engagement is critical as it lays the groundwork for increased patient prescriptions.
The number of prescriptions filled surged to over 1,200 in Q2 compared to 300 in Q1, illustrating a healthy uptake of the drug in clinical practice. Furthermore, the company has secured coverage for Cardamist with more than 50% of commercially insured lives, an essential milestone that enhances patient access to the treatment. This improvement in coverage is expected to facilitate increased prescription rates in the coming quarters.
| Metric | Q2 2026 | YoY | QoQ |
|---|---|---|---|
| Revenue | $0.6M | N/A | N/A |
| Unique Prescribers | 800+ | N/A | +400% |
| Total Prescriptions | 1,200+ | N/A | +300% |
| Commercial Coverage | 50%+ | N/A | +25% |
Strategic Focus on Patient Activation Initiatives
As Milestone Pharmaceuticals moves into the second half of the year, the company plans to enhance its patient activation efforts now that commercial coverage has crossed the 50% threshold. The strategy involves targeted digital marketing campaigns designed to raise awareness of Cardamist among patients, encouraging them to discuss the medication with their healthcare providers. This initiative is expected to create a positive feedback loop, whereby increased patient inquiries will drive further prescriptions.
Lorenz Muller, Chief Commercial Officer, emphasized that the patient activation campaign will not be direct-to-consumer advertising but rather focused digital outreach to ensure that patients are informed and can easily discuss Cardamist with their doctors. The campaign will leverage platforms such as social media and medical websites to reach potential patients effectively. As awareness grows, the company anticipates a corresponding increase in prescription rates as physicians feel more confident prescribing Cardamist when patients express interest.
Financials Reflect Early Launch Costs
Despite the promising market signals, Milestone recorded a net loss of $28.6 million in Q2 2026, compared to a loss of $13 million in the same period last year. The increase in losses is attributable to heightened selling, general, and administrative expenses linked to the ongoing launch of Cardamist. Specifically, these expenses reached $22.6 million in Q2, up from $8.9 million in Q2 2025, reflecting the investments made to support the product's commercial introduction.
Research and development costs also decreased to $3.5 million in Q2 2026 from $3.7 million in the previous year, showing a strategic focus on managing operational expenditures while ramping up sales efforts.
Analyst Q&A Insights
During the Q&A session, analysts sought clarity on the prescribing trends and patient engagement strategies. Joseph Olivetto, CEO, noted that the increase in unique prescribers, including a healthy mix of electrophysiologists and general cardiologists, bodes well for the long-term adoption of Cardamist. The company is focused on deepening relationships with early adopters and expanding its prescriber base further.
The dialogue also highlighted the potential for repeat prescriptions as physicians gain experience with Cardamist. Early indications suggest that patient experiences are leading to increased subsequent prescriptions, reinforcing the product’s value proposition.
Frequently Asked Questions
Did Milestone Pharmaceuticals Inc. Common Shares beat earnings estimates in Q2 2026?
No, Milestone reported a net loss of $28.6 million, or $0.21 per share, which did not meet expectations.
How many unique prescribers wrote prescriptions for Cardamist in Q2 2026?
Over 800 unique prescribers wrote prescriptions for Cardamist in Q2 2026, a significant increase from approximately 200 in Q1 2026.
What percentage of commercially insured lives are now covered for Cardamist?
As of now, more than 50% of commercially insured lives are covered for Cardamist, a notable increase from 25% at the end of Q2.
What were the total prescriptions for Cardamist in Q2 2026?
Total prescriptions for Cardamist in Q2 2026 exceeded 1,200, compared to around 300 in Q1, indicating strong adoption.
In summary, Milestone Pharmaceuticals has achieved significant milestones in the early stages of Cardamist's launch, with promising metrics that suggest a solid foundation for future growth. The ongoing focus on patient activation and increased prescriber engagement will be critical as the company navigates the second half of 2026.
This analysis is based on public earnings call materials and is not investment advice.
